Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial
Posted inCardiology Clinical Updates news Specialties

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial

The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients with both abnormalities face higher hyperkalemia risk.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inCardiology Clinical Updates news Specialties

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.